Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallium fibroblast activation protein inhibitor (Ga-FAPI) refers to a class of target-specific diagnostic radiopharmaceuticals designed for positron emission tomography (PET) imaging. Developed originally by researchers at Heidelberg University Hospital and subsequently licensed to SOFIE Biosciences and GE HealthCare, these agents target fibroblast activation protein alpha (FAP), a cell-surface glycoprotein highly overexpressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment of various solid tumors, as well as on activated fibroblasts in chronic inflammatory and fibrotic diseases. Prominent members of this class include [68Ga]Ga-FAPI-04 and [68Ga]Ga-FAPI-46. By binding specifically to FAP, Ga-FAPI PET imaging provides high-contrast visualization of the tumor stroma and active fibrotic/inflammatory lesions with minimal background uptake in normal tissues, offering a promising alternative or complement to conventional [18F]FDG PET imaging. Ga-FAPI is currently being evaluated in clinical trials for staging and monitoring various malignancies (such as pancreatic, breast, and head and neck cancers) as well as chronic inflammatory and fibrosing conditions (including polymyalgia rheumatica, giant cell arteritis, rheumatoid arthritis, and liver fibrosis).
| Indication | Highest phase | Status |
|---|---|---|
| breast cancer and precursor lesions | In development | Active |
| endometriosis | In development | Active |
| gastrointestinal cancers and precursor lesions | In development | Active |
| giant cell arteritis (GCA) | In development | Active |
| head and neck cancers | In development | Active |
| liver fibrosis (hepatic fibrosis) | In development | Active |
| lung cancer and precursor lesions | In development | Active |
| pancreatic cancer and precursor lesions | In development | Active |
| polymyalgia rheumatica (PMR) | In development | Active |
| primary myelofibrosis (PMF) | In development | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Patent families, expiry dates and exclusivities are in the full profile.
Lead indication: breast cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gallium fibroblast activation protein inhibitor.
Work on gallium fibroblast activation protein inhibitor? Claim this page to correct or add information. Claim this page